1. R.Aejmelaeus, T.Mets„-Ketel„, P.Laippala, H.Alho, T.Solakvi. Ubiquinol-10 and total peroxyl radical trapping capacity of LDL lipoproteins during aging: the effects of Q-10 supplementation. Molecular Aspects of Medicine, 1997; 18:Suppl:s113-20.
2. R.Alleva, M.Tomasetti, S.Bompadre, G.P.Littarru. Oxidation of LDL and their subfractions: kinetic aspects and CoQ10 content. Molecular Aspects of Medicine, 1997;18:Suppl:s105-12.
3. E.Baggio, R.Gandini, A.C.Plancher, M.Passeri, G.Carmosino. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Molecular Aspects of Medicine 1994;15 Suppl:s287-94.
4. A.M.Bargossi, M.Battino, A.Gaddi, P.L.Fiorella, G.Grossi, G.Barozzi, R.Di Giulio, G.Descovich, S.Sassi, M.L.Genova. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res 1994;24(3):171-6.
5. R.F.Beyer, L.Ernster. The antioxidant role of coenzyme Q. Highlights in Ubiquinone research. G.Lenaz, O.Barnabei, A.Rabbi, M.Battino, (eds) Taylor and Francis, London, 1990, pp.191-213.
6. M.Chello, P.Mastroroberto, R.Romano, E.Bevacqua, D.Pantaleo, R.Ascione, A.R.Marchese, N.Spampinato. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg 1994 Nov;58(5):1427-32.
7. M.Chello, P.Mastroroberto, R.Romano, P.Castaldo, E.Bevacqua, A.R.Marchese. Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping. J Cardiovasc Surg (Torino) 1996 Jun;37(3):229-35.
8. Y.F.Chen, Y.T.Lin, S.C.Wu. Effectiveness of coenzyme Q10 on myocardial preservation during hypothermic cardioplegic arrest. J Thorac Cardiovasc Surg 1994 Jan;107(1):242-7.
9. A.Constantinescu, J.J.Maguire, L.Packer. Interactions between ubiquinones and vitamins in membranes and cells. Molecular Aspects of Medicine, 1994;15 Suppl:s57-s65.
10. F.L.Crane, Y.Hatefi, R.I.Lester, C.Widmer. Isolation of a quinone from beef heart mitochondria. Biochimica et Biophys. Acta 1957;25:2201.
11. F.L.Crane, D.J.MorrŠ. Evidence for coenzyme Q function in Golgi membranes. In: K.Folkers, Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam; 1977; p.77-86.
12. F.L.Crane, I.L.Sun, R.Barr, D.J.MorrŠ. Coenzyme Q in Golgi apparatus membrane redox activity and proton uptake. K.Folkers, Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam; 1984;4:77-86.
13. J.A.Crestanello, J.Kamelgard, D.M.Lingle, S.A.Mortensen, M.Rhode, G.J.Whitman. Elucidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10 pretreatment. J Thorac Cardiovasc Surg, 1996 Feb;111(2) 443-50.
14. V.Digiesi, F.Cantini, A.Oradei, G.Bisi, G.C.Guarino, A.Brocchi, F.Bellandi, M.Mancini, G.P.Littarru. Coenzyme Q10 in essential hypertension. Molecular Aspects of Medicine, 1994;15 Suppl:s257-63.
15. L.Ernster, P.Forsmark-Andree. Ubiquinol: an endogenous antioxidant in aerobic organisms. K.Folkers, S.A.Mortensen, G.P.Littarru, T.Yamagami, and G.Lenaz (eds) The Clinical Investigator, 1993;71(8):S60-5.
16. K.Folkers, G.P.Littarru, L.Ho, T.M.Runge, S.Havanonda, D.Cooley. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int Z Vitaminforsch, 1970; 40(3):380-90.
17. K.Folkers, S.Vadhanavikit, S.A.Mortensen. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10 . Proc Natl Acad Sci U S A, 1985 Feb; 82:3, 901-4.
18. K.Folkers, P.H.Langsjoen, R.Willis, P.Richardson, L.J.Xia, C.Q.Ye, H.Tamagawa. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A, 87: 22, 1990 Nov, 8931-4.
19. G.Ghirlanda, A.Oradei, A.Manto, S.Lippa, L.Uccioli, S.Caputo, A.V.Greco, G.P.Littarru. Evidence of plasma CoQ10 -lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993 Mar;33(3):226-9.
20. M.Hamada, Y.Kazatani, T.Ochi, T.Ito, T.Kokubu. Correlation between serum CoQ10 level and myocardial contractility in hypertensive patients. Biomedical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam 1984;4:263-70.
21. K.Hashiba, K.Kuramoto, Z.Ishimi, K.Kato, K.Seki, K.Taniguchi, T.Taya, F.Terawasa, S.Torii, J.Fijii, N.Yamazaki and H.Watanabe, Heart 1972;4:1579-89 [in Japanese].
22. Y.Hiasa, T.Ishida, T.Maeda, K.Iwanc, T.Aihara, and H.Mori. Effects of coenzyme Q10 on exercise tolerance in patients with stable angina pectoris. K.Folkers, Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam; 1984;4:291-301.
23. K.U.Ingold, V.W.Bowry, R.Stocker, C.Walling. Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc Natl Acad Sci U S A 1993 Jan 1;90(1):45-9.
24. T.Iwabuchi, N.Kato, N.Goto, Y.Higuchi, S.Takaola, Y.Iwaki, E.Shidara, M.Yoshimura and J.Atarashi. Jpn. J Clin. Exp. Med. 1972;49:2604-8 (in Japanese).
25. W.V.Judy, J.H.Hall, P.D.Toth, K.Folkers. Double blind-double crossover study of coenzyme Q10 in heart failure. In: K.Folkers and Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam; 1986;5:315-23.
26. W.V.Judy, K.Folkers, J.H.Hall. Improved long-term survival in coenzyme Q10 treated congestive heart failure patients compared to conventionally treated patients. K.Folkers, G.P.Littarru and T.Yamagami (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam; 1991;6:291-8.
27. W.V.Judy, W.W.Stogsdill, K.Folkers. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clinical Investigator 1993;71(8 Suppl):S155-61.
28. T.Kamikawa, A.Kobayashi, T.Yamashita, H.Hayashi, and N.Yamazaki. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. American. Journal of Cardiology 1985; 56:247-51.
29. T.Kato, S.Yoneda, T.Kako, M.Koketsu, I.Hayano, T.Fujinami. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease. Int J Clin Pharmacol Ther Toxicol 1990 Mar; 28 (3):123-6.
30. T.Kishi, T.Okamoto, N.Kanamori, T.Yamagami, H.Kishi, A.Onada and K.Folkers. Estimation od plasma levels of coenzyme Q10 and relationship to oral dosage. K.Folkers, Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier/North-Holland Press;1981;3:67-89.
31. N.Kitamura, A.Yamaguchi, M.Otaki, O.Sawatani, T.Minoji, H.Tamura, and M.Atobe. Myocardial tissue level of coenzyme Q10 in patients with cardiac failure. K.Folkers and Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam; 1984;4:243-52.
32. B.Kuklinski, E.Weissenbacher, A.Fahnrich. Coenzyme Q10 and antioxidants in acute myocardial infarction. Molecular Aspects of Medicine, 1994;15 Suppl:s143-7.
33. R.Laaksonen, K.Jokelainen, T.Sahi, M.J.Tikkanen, J.J.Himberg. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995 Jan;57(1):62-6.
34. P.H.Langsjoen, S.Vadhanavikit, K.Folkers. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10 . Proceedings of the National Acadademy of Sciences, U.S.A. 1985; 82:4240-4.
35. P.H.Langsjoen, P.H.Langsjoen, K.Folkers. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. American. Journal of Cardiology, 1990, Feb 15; 65(7):521-3.
36. P.H.Langsjoen, P.H.Langsjoen, K.Folkers. Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. K.Folkers, S.A.Mortensen, G.P.Littarru, T.Yamagami, and G.Lenaz (eds) Clinical Investigator,1993;71:S140-4.
37. H.A.Langsjoen, P.H.Langsjoen, P.H.Langsjoen, R.Willis, K.Folkers. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study.Molecular Aspects of Medicine, 1994;15 Suppl:s165-75.
38. P.H.Langsjoen, P.H.Langsjoen, R.Willis, K.Folkers. Treatment of essential hypertension with coenzyme Q10 . The Molecular Aspects of Medicine, 1994;15 Suppl:s265-72.
39. P.H.Langsjoen, A.Langsjoen, R.Willis, K.Folkers. Treatment of Hypertrophic Cardiomyopathy with Coenzyme Q10 . Molecular Aspects of Medicine, 1997;18 Suppl.:s145-51.
40. P.H.Langsjoen, A.Langsjoen, R.Willis, K.Folkers. The Aging Heart: Reversal of Diastolic Dysfunction Through the Use of Oral CoQ10 in the Elderly. Anti-Aging Medical Therapeutics, 1997b, R.M.Klatz and R.Goldman (eds), Health Quest Publications, pp.113-120.
41. A.Lawen, R.D.Martinius, G.McMullen, P.Nagley, F.Vaillant, E.J.Wolvetang, A.W.Linnane. The universality of bioenergetic disease: The role of mitochondrial mutation and the putative inter-relationship between mitochondria and plasma membrane NADH oxidoreductase. Molecular Aspects of Medicine, 1994;15: s13-s27.
42. G.Lenaz and G.Parenti Castelli. Biological Membranes G. Benga (ed), CRC Press, Boca Raton, USA 1984 Vol. I.
43. G.Lenaz and D.Esposti. Physical properties of ubiquinones in model systems and membranes. In: G.Lenaz (ed). Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone. John Wiley & Sons; 1985; Chapter IV, p.83-105.
44. G.Lenaz. The role of mobility of redox components in the inner mitochondrial membrane. J. Membr. Biol. 1988;104:193-209.
45. G.Lenaz, R.Fato, C.Castelluccio, M.Battino, M.Cavazzoni, H.Rauchova, and G.P.Castelli. Coenzyme Q saturation kinetics of mitochondrial enzymes: Theory, experimental aspects and biomedical implications. K.Folkers, T.Yamagami, and G.P.Littarru (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam;1991;6:11-8.
46. A.W.Linnane, C.Zhang, A.Baumer, P.Nagley. Mitochondrial DNA mutation and the aging process: bioenergy and pharmacological intervention. Mutation Research 1992;275:195-208.
47. G.P.Littarru, L.Ho, K.Folkers. Deficiency of Coenzyme Q10 in human heart disease. Part I and II. Internat. J. Vit. Nutr. Res.1972;42,(2):291, 42(3):413.
48. R.D.Martinius, A.W.Linnane, P.Nagley. Growth of human namalwa cells lacking oxidative phosphorylation can be sustained by redox compounds. potassium ferricyanide or coenzyme Q10 putatively acting through the plasma membrane oxidase. Biochem. Mol. Biol. Internat. 1993;31:997-1005.
49. P.Mitchell. Possible molecular mechanism of the protonmotive function of cytochrome systems. J. Theor. Biol. 1976;62:327-367.
50. P.L.Montaldo, G.Fadda, S.Salis, G.Satta, M.Tronci, R.DiCesare, R.Reina, A.Concu. Effects of the prolonged administration of coenzyme Q10 in borderline hypertensive patients: a hemodynamic study. Biomedical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam 1991; 6:417-24.
51. C.Morisco, B.Trimarco, M.Condorelli. Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long-term multicenter randomized study. K.Folkers, S.A.Mortensen, G.P. Littarru, T.Yamagami, and G.Lenaz (guest eds) Clinical Investigator 1993;71:S134-6.
52. C.Morisco, A.Nappi, L.Argenziano, D.Sarno, D.Fonatana, M.Imbriaco, A.Cuocolo, et al. Noninvasive evaluation of cardiac hemody-namics during exercise in patients with chronic heart failure: Effects of short-term coenzyme Q10 treatment. Molecular Aspects of Medicine, 1994;15 Suppl:s155-63.
53. S.A.Mortensen, S.Vadhanavikit, U.Baandrup, K.Folkers. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Exp Clin Res 1985;11(8):581-93.
54. S.A.Mortensen, P.Bouchelouche, K.Muratsu, K.Folkers. Clinical decline and relapse of cardiac patients on coenzyme Q10 withdrawal. K.Folkers and Y.Yamamura (eds) Biomed. and Clin. Aspects of Coenzyme Q. Elsevier, Amsterdam; 1986;5:281-90.
55. S.A.Mortensen, S.Vadhanavikit, K.Muratsu, K.Folkers. Coenzyme Q10 : clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React, 1990;12(3):155-62.
56. S.A.Mortensen, A.Leth, E.Agner, M.Rohde. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Molecular Aspects of Medicine, 1997;18:Suppl:s137-44.
57. R.A.Morton, G.M.Wilson, J.S.Lowe and W.M.F.Leat. Ubiquinone. Chemical Industry, 1957, p.1649.
58. M.Nagano, M.Saito, S.Mochizuki, S.Anazawa, S.Tomizuka, M.Kawamura, and H.Aoki. J. Adult Dis., 6:281-6 [In Japanese].
59. T.Nakamura, H.Sanma, M.Himeno, and K.Kato. Transfer of exogenous coenzyme Q10 to the inner membrane of heart mitochondria in rats. K.Folkers, Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier/North-Holland Press; 1980;2:3-14.
60. T.Oda. Effect of coenzyme Q10 on load-induced cardiac dysfunction: Double blind study and investigation of dose-response relationship. Highlights in Ubiquinone Research. G.Lenaz, O.Barnabei, A.Rabbi, M.Battino, (eds) Taylor and Francis, London, 1990, pp.232-237.
61. T.Oda. Recovery of the Frank-Starling mechanism by coenzyme Q10 in patients with load-induced contractility depression. Molecular Aspects of Medicine, 1994;15 (Supplement):149-54.
62. T.Ozawa. Formation of oxygen radicals in the electron transfer chain and antioxidant properties of coenzyme Q. G.Lenaz (ed). Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone. John Wiley & Sons, 1985; Chapter XXI, p. 441-56.
63. A.Palomaki, K.Malminiemi, T.Metsa-Ketela. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS Letter 1997 Jun 30;410(2-3):254-8
64. B.Permanetter, W.Rossy, G.Klein, F.Weingartner, K.F.Seidl, H.Blomer. Ubiquinone (coenzyme Q10 ) in the long-term treatment of idiopathic dilated cardiomyopathy. European Heart J 1992 Nov;13 (11):1528-33.
65. L.Poggesi, G.Galanti, M.Comeglio, L.Toncelli and M.Vinci. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. A medium-term randomized double-blind study versus placebo. Current Therapeutic Research 1991;49(5):878-86.
66. F.Rengo, P.Abete, P.Landino, D.Leosco, F.Covelluzzi, D.Vitale, N.Ferrara et al. Role of metabolic therapy in cardiovascular disease. K.Folkers, S.A.Mortensen, G.P.Littarru, T.Yamagami, and G.Lenaz (guest eds) The Clinical Investigator, 1993;71:S124-8.
67. P.Richardson, J.Drzewoski, J.Ellis, S.Shizukuishi, K.Takemura, L.Baker, K.Folkers. Reduction of elevated blood pressure by coenzyme Q10 . Biomedical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam, 1981;3:229-34.
68. E.Rossi, A.Lombardo, M.Testa, S.Lippa, A.Oradei, G.P.Littarru, U.Manzoli et al. Coenzyme Q10 in ischaemic cardiopathy. K.Folkers, T.Yamagami, andG.P.Littarru (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam;1991;6:321-6.
69. H.Rudney, A.M.D.Nambudiri, S.Ranganathan. The regulation of the synthesis of coenzyme Q in fibroblasts and in heart muscle. K.Folkers, Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier/North-Holland Press;1981;3:279-90.
70. F.Schardt, D.Welzel, W.Schiess, and K.Toda. Effect of coenzyme Q10 on ischaemia-induced ST-segment depression: A double blind, placebo-controlled crossover study. K.Folkers, T.Yamagami, and G.P.Littarru (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam; 1986; 6:385-403.
71. W.Schneeberger, J.Muller-Steinwachs, L.P.Anda, W.Fuchs, F.Zilliken, K.Lyson, K.Folkers et al. A clinical double blind and crossover trial with coenzyme Q10 on patients with cardiac disease. K.Folkers, Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam, 1986;5:325-33.
72. G.Serra, F.Lissoni, C.Piemonti, C.Mazzola. Evaluation of CoQ10 in patients with moderate heart failure and chronic stable effort angina. K.Folkers, T.Yamagami, and G.P.Littarru (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam; 1991;6: p.327-38.
73. A.M.Soja, S.A.Mortensen. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Molecular Aspects of Medicine, 1997;18 Suppl:S159-S168.
74. M.Sunamori, H.Tanaka, T.Maruyama, I.Sultan, T.Sakamoto, A.Suzuki. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization. Cardiovasc Drugs Ther 1991 Mar;5 Suppl 2:297-300.
75. K.Swedberg, C.Hoffman-Bang, N.Rehnqvist, H.strom. Coenzyme Q10 as an adjunctive in treatment of congestive heart failure. J Cardiac Failure, 1995;1:101-7.
76. D.P.Taggart, M.Jenkins, J.Hooper, L.Hadjinikolas, M.Kemp, D.Hue, G.Bennett. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Annals of Thoracic Surgery, 1996 Mar; 61(3):829-33.
77. J.Tanaka, R.Tominaga, M.Yoshitoshi, K.Matsui, M.Komori, A.Sese, H.Yasui, K.Tokunaga. Coenzyme Q10 : the prophylactic effect on low cardiac output following cardiac valve replacement. Annals of Thoracic Surgery 1982 Feb;33(2):145-51.
78. S.R.Thomas, J.Neuzil, R.Stocker. Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler Thromb Vasc Biol 1996 May;16(5):687-96.
79. S.R.Thomas, J.Neuzil, R.Stocker. Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? Molecular Aspects of Medicine, 1997; 18:Suppl:s85-s103
80. T.Tsuyuasaki, C.Noro, R.Kikawada. Mechanocardiography of ischemic or hypertensive heart disease. Y.Yamamura and K.Folkers (eds) Biomedical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam, 1980;2:273-88.
81. J.P.H.VanFraechem, C.Picalausa, K.Folkers. Effects of CoQ10 on physical performance and recovery in myocardial failure. K.Folkers and Y.Yamamura (eds) Biomedical and clinical aspects of coenzyme Q. Elsevier, Amsterdam;1986;5:371-7.
82. J.M.Villalba, F.Navarro, C.Gomez-Diaz, A.Arroyo, R.I.Bello and P.Navas P. Role of cytochrome b5 reductase on the antioxidant function of coenzyme Q in the plasma membrane. G.P.Littarru, M.Alleva, M.Battino and K.Folkers (guest eds) Molecular Aspects of Medicine. 1997;18 Suppl:s7-s13.
83. R.A.Willis, K.Folkers, J.L.Tucker, C.Q.Ye, L.J.Xia, H.Tamagawa. Lovastatin decreases coenzyme Q levels in rats. Procedings of the National Academy of Sciences U S A, 1990 Nov;87(22):8928-30.
84. M.F.Wilson, W.H.Frishman, T.Giles, G.Sethi, S.Greenberg, J.Brackett. Coenzyme Q10 therapy and exercise duration in stable angina. K.Folkers, G.P.Littarru and T.Yamagami (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam; 1991;6:339-48.
85. T.Yamagami, N.Shibata, K.Folkers. Study of Coenzyme Q10 in essential hypertension. K.Folkers, Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam, 1977, pp.231-242.
86. T.Yamagami, M.Takagi, H.Akagami, H.Kubo, S.Toyama, T.Okamoto, T.Kishi, K.Folkers. Effect of coenzyme Q10 on essential hypertension, a double blind controlled study. Biomedical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam,1986;5:337-43.
87. Y.Yamamura Jpn. Circ. J. 1967a;31.
88. Y.Yamamura, T.Ishiyama, Y.Morita, and T.Yamagami. Sogo Rinsho 1967b;16:1564-72 (in Japanese).
89. Y.Yamamura, T.Ishiyama, Y.Morita, N.Tsukamoto, J.Kobayashi and T.Yamagami. Sogo Rinsho (Clinic All-round) 1968;17:1057-65 (in Japanese).
90. Y.Yamamura. Clinical status of Coenzyme Q and prospects. K.Folkers and Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam; 1977, pp.281-298.
91. Y.Yamamura. A survey of the therapeutic uses of coenzyme Q. G. Lenaz (ed). Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone. John Wiley & Sons 1985; pp.479-505.
92. H.Yokoyama, D.M.Lingle, J.A.Crestanello, J.Kamelgard, B.R.Kott, R.Momeni, J.Millili, S.A.Mortensen, G.J.Whitman. Coenzyme Q10 protects coronary endothelial function from ischemia reperfusion injury via an antioxidant effect. Surgery Aug 1996;120(2):189-96.

International CoenzymeQ10 Association - Institute of Biochemistry - University Politecnic of Marche

Via Ranieri 60131 Ancona - Italy - tel: +39 071 2204674 - fax: +39 071 2801932 - e-mail: g.p.littarru@univpm.it